
Bristol-Myers Squibb Company
BMYAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 30, 2026 | Truist Financial | Srikripa Devarakonda | $70.00(+14%) | $61.39 | StreetInsider |
| Oct 26, 2026 | Piper Sandler | $78.00(+27%) | $61.48 | TheFly | |
| Oct 12, 2026 | Jefferies | Akash Tewari | $76.00(+32%) | $57.58 | TheFly |
| Oct 8, 2026 | Cantor Fitzgerald | Carter Gould | $53.00(-11%) | $59.70 | TheFly |
| Oct 7, 2026 | Morgan Stanley | Terence Flynn | $41.00(-31%) | $59.70 | TheFly |
| Oct 5, 2026 | Leerink Partners | $59.00(-0%) | $59.02 | TheFly | |
| Sep 23, 2026 | Goldman Sachs | Asad Haider | $63.00(+1%) | $62.25 | StreetInsider |
| Sep 16, 2026 | Piper Sandler | $82.00(+29%) | $63.73 | TheFly | |
| Sep 10, 2026 | HSBC | $65.00(+1%) | $64.41 | TheFly | |
| Aug 5, 2026 | Roth Capital | $75.00(+18%) | $63.47 | TheFly | |
| Aug 5, 2026 | Argus Research | Jasper Hellweg | $75.00(+14%) | $65.89 | TheFly |
| Aug 4, 2026 | RBC Capital | Trung Huynh | $64.00(-1%) | $64.73 | StreetInsider |
| Jul 31, 2026 | Cantor Fitzgerald | Carter Gould | $59.00(-7%) | $63.67 | TheFly |
| Jul 31, 2026 | Guggenheim | Seamus Fernandez | $75.00(+16%) | $64.86 | TheFly |
| Jul 31, 2026 | Wells Fargo | $65.00(+0%) | $64.86 | TheFly | |
| Apr 8, 2026 | Cantor Fitzgerald | $54.00(-9%) | $59.20 | TheFly | |
| Mar 6, 2026 | UBS | Michael Yee | $70.00(+17%) | $59.78 | StreetInsider |
| Feb 24, 2026 | RBC Capital | Trung Huynh | $60.00(-3%) | $61.60 | StreetInsider |
| Feb 23, 2026 | Piper Sandler | $75.00(+24%) | $60.66 | TheFly | |
| Feb 19, 2026 | Barclays | $75.00(+24%) | $60.30 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Morgan Stanley | maintain | Underweight | Oct 30, 2026 |
| Piper Sandler | maintain | Overweight | Oct 26, 2026 |
| Wells Fargo | maintain | Equal Weight | Oct 13, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Oct 8, 2026 |
| Morgan Stanley | maintain | Underweight | Oct 7, 2026 |
| Leerink Partners | downgrade | Outperform →Market Perform | Oct 5, 2026 |
| Piper Sandler | maintain | Overweight | Sep 16, 2026 |
| HSBC | maintain | Hold | Sep 10, 2026 |
| Argus Research | upgrade | Hold →Buy | Aug 5, 2026 |
| Citigroup | maintain | Neutral | Aug 3, 2026 |
| RBC Capital | maintain | Sector Perform | Jul 31, 2026 |
| JP Morgan | maintain | Overweight | Jul 31, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Jul 31, 2026 |
| Wells Fargo | maintain | Equal Weight | Jul 31, 2026 |
| Guggenheim | maintain | Buy | Jul 31, 2026 |
| Truist Securities | maintain | Buy | Jul 31, 2026 |
| B of A Securities | maintain | Buy | Jul 10, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Jul 6, 2026 |
| B of A Securities | maintain | Buy | Apr 9, 2026 |
| Guggenheim | maintain | Buy | Apr 8, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Apr 8, 2026 |
| HSBC | maintain | Hold | Mar 17, 2026 |
| Piper Sandler | maintain | Overweight | Feb 23, 2026 |
| Citigroup | maintain | Neutral | Feb 6, 2026 |
| Wells Fargo | maintain | Equal Weight | Feb 6, 2026 |
Earnings History
Next report: Feb 4, 2027 · EPS est. $1.56| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 29, 2026 | $1.35 | $1.10 | $13.07B | $12.72B |
| Jul 30, 2026 | $2.04 | $1.60 | $12.97B | $11.74B |
| Apr 30, 2026 | $1.58 | $1.42 | $11.49B | $10.93B |
| Feb 5, 2026 | $1.26 | $1.23 | $12.50B | $12.28B |
| Oct 30, 2025 | $1.63 | $1.52 | $12.22B | $11.85B |
| Jul 31, 2025 | $1.46 | $1.09 | $12.27B | $11.44B |
| Apr 24, 2025 | $1.80 | $1.49 | $11.20B | $10.70B |
| Feb 6, 2025 | $1.67 | $1.47 | $12.34B | $11.57B |
News
The average pharmaceutical stock yields 1.4%, while Bristol Myers Squibb yields 4%. Bristol Myers Squibb is working through a transition period as older drugs lose patent protection.
Bristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while diversifying into gene editing and treatments for acute pain.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos.
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know which numbers actually matter before 2027 arrives.
They are so much more than just dividend stocks.
Associated Banc Corp bought a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 48,234 shares of the biopharmaceutical company's stock, valued at approximately $3,010,000. A number of other institutional investors and
These dividend stocks with economic moats offer durable payouts.
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products. Bristol Myers Squibb offers a high-margin portfolio focused on oncology and hematology with a significantly lower valuation multiple.
Bristol Myers Squibb gains 3% after beating third-quarter estimates, as its Growth Portfolio and promising pipeline support revenue prospects despite generic competition.
Bristol-Myers Squibb is downgraded to 'Hold' as its current valuation appears optimistic ahead of looming patent cliffs. BMY's Growth Portfolio now comprises ~59% of revenues, with 8 medicines annualizing above $1 billion, partially offsetting legacy portfolio declines. DCF analysis values BMY at $61.19 per share, nearly matching the current price, highlighting limited upside even with near flat forward revenue growth.
BMY raises its 2026 revenue outlook on strong Growth Portfolio sales, even as earnings pressure, patent expirations and drug launch challenges remain in focus.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Bristol Myers Squibb NYSE: BMY raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a series of clinical readouts and manufacturing investments intended to support its next generation of launches.
Bristol Myers Squibb's Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain to $13.1 billion. Adjusted EPS fell 17% to $1.35, but mostly because of deal accounting, not a weaker core business.
Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.63 per share a year ago.
Bristol Myers Squibb raised its full-year revenue outlook due to higher third-quarter revenue.